Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia (FPI)

This study is ongoing, but not recruiting participants.
Laval University
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute Identifier:
First received: January 31, 2008
Last updated: April 12, 2013
Last verified: April 2013

The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. Our hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication- fenofibrate.

Condition Intervention Phase
Drug: fenofibrate
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Impact of Genetic Determinants of Fenofibrate's Pharmacogenetics on Lipid Response

Resource links provided by NLM:

Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Triglyceride lowering response [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters based on genotype [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2008
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
High drug metabolism genotype
Drug: fenofibrate
Fenofibrate 145mg tablets once daily for 4 weeks
Other Name: TriCor® 145mg tablets
Active Comparator: 2
Low drug metabolism genotype
Drug: fenofibrate
Fenofibrate 145mg tablets once daily for 4 weeks
Other Name: TriCor® 145mg tablets

Detailed Description:

We seek to screen over 200 subjects for select candidate genes to serve as a source of subjects which may participate in a genotype guided investigation as to the predictability of response based on genotype. Response endpoints relate to lipid parameters and other variables of interest to cardiovascular endpoints. Subjects with genotypes of interest would then be enrolled into a short term clinical trial evaluating their response to fenofibrate based on their genetic profile ascertained from the screening phase. We hope to evaluate ~50 subjects in the second phase.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18-75 year old
  • Be willing to participate in the study and attend the scheduled clinic exams
  • Consent to taking lipid lowering therapy for 4 weeks and if necessary discontinue lipid lowering agents for a period of 8 weeks

Exclusion Criteria:

  • <18 years of age
  • History of liver, kidney, pancreas, pancreatitis, gall bladder disease or malabsorption (Crohn's disease etc.)
  • Use of insulin or currently taking warfarin
  • Pregnant women or women of childbearing potential not using an acceptable form of contraception
  • History of an allergy or hypersensitivity to fenofibrate
  • Investigational drug use within 30 days of the study
  • A disease that, in the opinion, of the PI, would put the subject at risk during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00613613

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Laval University
Principal Investigator: Robert J. Straka University of Minnesota - Clinical and Translational Science Institute
  More Information

No publications provided

Responsible Party: University of Minnesota - Clinical and Translational Science Institute Identifier: NCT00613613     History of Changes
Other Study ID Numbers: 0708M15441, AHA Grant #0755839Z
Study First Received: January 31, 2008
Last Updated: April 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014